SYRE — Spyre Therapeutics Income Statement
0.000.00%
- $1.19bn
- $894.18m
- $0.89m
Annual income statement for Spyre Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 18.7 | 2.33 | 0.886 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 80.3 | 81.5 | 84.4 | 87.1 | 243 |
Operating Profit | -80.3 | -81.5 | -65.6 | -84.8 | -242 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -78.3 | -80.9 | -65.7 | -84 | -339 |
Provision for Income Taxes | |||||
Net Income After Taxes | -78.3 | -80.9 | -65.8 | -83.8 | -339 |
Net Income Before Extraordinary Items | |||||
Net Income | -78.3 | -80.9 | -65.8 | -83.8 | -339 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -78.3 | -80.9 | -65.8 | -83.8 | -339 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -61.2 | -37.9 | -25 | -24.9 | -30.8 |